Remzi Bag
Pulmonary Disease · Jacksonville, FLNPI 1609073881
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 40.1% of the total. Reporting peaked in 2019 at $3,532 and has fallen 94.3% since, to $200 in 2023.
Across 19 payments — averaging $336.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$3K
- Bayer$2K
- Cipla USA Inc.$1K
- Actelion Pharmaceuticals, Ltd$715
- United Therapeutics Corporation$214
- Boehringer Ingelheim$128
- plus $124 from 2 others
Across 97 payments — averaging $5676.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$235K
- Medtronic$158K
- Sanofi US Services Inc.$129K
- Janssen Research & Development, LLC$29K
- Sanofi-aventis U.S. LLC$90
What the payments were for
- Consulting fees$1,32521%
- Speaking & faculty fees$3,57456%
- Travel & lodging$76912%
- Food & beverage$5138%
- Education$2143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 5 | $2,566 |
| Bayer | 2 | $1,524 |
| Cipla USA Inc. | 1 | $1,125 |
| Actelion Pharmaceuticals, Ltd | 6 | $715 |
| United Therapeutics Corporation | 1 | $214 |
| Boehringer Ingelheim | 1 | $128 |
| Janssen Research & Development, LLC | 2 | $111 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,395 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 52 | $14,849 |
| EliquisApixaban | 18 | $13,483 |
| ColistimethateColistin (Colistimethate Na) | 11 | $8,849 |
| Voriconazole | 18 | $4,706 |
| Tacrolimus | 29 | $2,787 |
| Azithromycin | 105 | $2,326 |
| Cyclosporine ModifiedCyclosporine, Modified | 16 | $1,678 |
| Montelukast Sodium | 80 | $868 |
| Prednisone | 117 | $843 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 117 | $658 |
| Pantoprazole Sodium | 58 | $517 |
| Bumetanide | 12 | $415 |
| Omeprazole | 31 | $342 |
| Metoprolol Tartrate | 44 | $258 |
| Atorvastatin Calcium | 25 | $203 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.